Article

Numerous strategies may be needed to control IFIS

Intraoperative floppy iris syndrome (IFIS) can be approached in a number of ways depending on the surgical scenario, according to David Chang, MD, University of California, San Francisco.

Intraoperative floppy iris syndrome (IFIS) can be approached in a number of ways depending on the surgical scenario,according to David Chang, MD, University of California, San Francisco.

"There is great variability in how the iris responds among patients with IFIS," Dr. Chang said. "We have to control it, or itmay or may not work, which is why multiple strategies are needed."

The first approach that he uses, an ophthalmic viscosurgical device (OVD), provides good pupillary dilation in patients whoare taking tamsulosin (Flomax, Boehringer Ingelheim Pharmaceuticals), as Dr. Chang demonstrated in a mild case of IFIS.Gentle hydrodissection, horizontal chopping, and low flow are advised in these cases, he said. The key to using an OVD is toprolong its duration in the eye. He achieves visco mydriasis by refilling the eye with a proprietary OVD, 2.3% sodiumhyaluronate (Healon5, Advanced Medical Optics), as needed. However, he noted, there is a learning curve associated with theuse of this OVD.

Another strategy in patients with IFIS in whom an OVD alone may not work is the use of intracameral epinephrine, whichprovides pupillary rigidity and eliminates any billowing of the iris. In these cases, epinephrine is mixed with balanced saltsolution in a 1:4 ratio. Dr. Chang demonstrated a case in which epinephrine was used, there was no prolapse, and the irisbillowing stopped. In cases of severe IFIS, epinephrine may need more time to work.

When epinephrine is ineffective, Dr. Chang reported that he combines 2.3% sodium hyaluronate and epinephrine to dilate thepupil successfully.

In patients with a small pupil, iris retractors (available from Katena and FCI) may be used when intracameral epinephrine isineffective. Dr. Chang makes a separate stab incision from the phaco incision. The retractor forms the iris in a diamondconfiguration, which eliminates tenting of the iris and provides good exposure nasally for chopping.

The latest strategy is the disposable expansion ring. This device provides a 6-mm pupil diameter. The ring has a low profileallowing for easy access of the instrument to the eye. Dr. Chang said that, in his opinion, he considers one proprietary ring(Malyugin Ring, Microsurgical Technologies) to be among the easiest devices to use.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.